MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

Objective:

Primary Objective:

• To evaluate the efficacy of NTLA-2001, as measured by the composite risk of CV-related mortality and CV events (urgent HF visits and hospitalizations due to HF, arrhythmia, or stroke), compared to placebo

Secondary Objectives:

• To evaluate the effect of NTLA-2001 on serum TTR compared to placebo
• To evaluate the impact of NTLA-2001 on participant-reported CM-related symptoms and quality of life compared to placebo